AMRI — Stock Film
STOCK FILMSCENE 1/10AMRI · $21.74
Stock Expert AI presents
AMRI
Albany Molecular Research, Inc
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Albany Molecular Research, Inc. A quick introduction.

On the stock market since 1999, it operates in its own corner of the market. Now — the numbers.

on the stock market since 1999
$0 market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
94%Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients 94%Drug Product Manufacturing 6%
94% of all revenue comes from a single line: Active Pharmaceutical Ingredients.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 26% a year over the last 4 years. Red columns mark years that ended in a loss.

$226.7M
2012
$246.6M
2013
$276.6M
2014
$402.4M
2015
$570.5M
2016
In the vault right now:
$0
DEBT: $618.4M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 32% a year on average.

2
THE BRIGHT SIDE · 2/2
Sales are holding up

The company sells $570.5M a year; the problem isn’t sales — it’s costs running above that number.

1
THE RISKS · 1/2
The losses continue

A loss of $70.2M against $570.5M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, AMRI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AMRI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film